Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current pharmacotherapeutic strategies for overactive bladder.

Alan D Garely1, Lara J Burrows

  • 1Wintrop University Hospital, Mineola, New York, USA. Agarely@nshs.edu

Expert Opinion on Pharmacotherapy
|June 27, 2002
PubMed
Summary

Overactive bladder (OAB) treatment focuses on reducing symptoms like urgency and frequency. Tolterodine extended-release offers improved efficacy and tolerability over immediate-release formulations, particularly reducing dry mouth side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing Emergency Gynecologic Surgery Guidelines during COVID-19.

Journal of minimally invasive gynecology·2020
Same author

Thermal and Mechanical Pain Thresholds of Women With Provoked Localized Vulvodynia: A Pilot Study.

The Journal of the American Osteopathic Association·2019
Same author

The Evidence-based Vulvodynia Assessment Project. A National Registry for the Study of Vulvodynia.

The Journal of reproductive medicine·2015
Same author

In reply.

Obstetrics and gynecology·2015
Same author

Urogynecologic conditions: urinary incontinence.

FP essentials·2015
Same author

Urogynecologic conditions: interstitial cystitis/painful bladder syndrome.

FP essentials·2015

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Overactive bladder (OAB) is a common condition causing urinary urgency and frequency.
  • Anticholinergic drugs are first-line OAB treatment but can cause side effects like dry mouth.
  • Developing more tolerable OAB medications is a key research area.

Purpose of the Study:

  • To compare the efficacy and tolerability of tolterodine extended-release (ER) with immediate-release (IR) formulations for OAB.
  • To evaluate tolterodine ER's convenience and patient outcomes.

Main Methods:

  • Review of studies comparing tolterodine IR and oxybutynin IR.
  • Analysis of clinical trial data for tolterodine ER versus tolterodine IR.
  • Assessment of efficacy (symptom reduction) and tolerability (side effect profiles).

Related Experiment Videos

Main Results:

  • Tolterodine IR and oxybutynin IR show similar efficacy for OAB.
  • Tolterodine IR is better tolerated than oxybutynin IR, especially regarding dry mouth.
  • Tolterodine ER demonstrates enhanced efficacy and tolerability compared to tolterodine IR, with convenient once-daily dosing.

Conclusions:

  • Tolterodine ER is an effective and well-tolerated treatment option for overactive bladder.
  • The extended-release formulation improves convenience and patient outcomes for OAB management.
  • Tolterodine ER represents an advancement in OAB pharmacotherapy, offering better symptom control with fewer side effects.